本文選題：甘草次酸 + 肝靶向�。� 參考：《中南藥學》2016年08期

【摘要】：針對肝癌的普通化療藥因其對正常組織的毒副作用在臨床治療中受到了極大的限制,而靶向藥物利用自身對靶器官特殊的親和力使藥物在正常組織的分布減少從而使不良反應(yīng)大大降低,該優(yōu)勢在一定程度上彌補了普通化療藥的不足。甘草次酸以其有效的肝靶向性進入人們的視線,將它作為載體發(fā)揮肝靶向性的研究日益受到人們的重視,該文就目前在肝靶向研究中對甘草次酸的結(jié)構(gòu)修飾和相關(guān)納米制劑的研究現(xiàn)狀進行總結(jié),為甘草次酸的肝靶向制劑研究提供參考依據(jù)。
[Abstract]:The common chemotherapeutic agents for liver cancer are greatly restricted in clinical treatment because of their toxic and side effects on normal tissues. Target drugs make use of their own special affinity to target organs to reduce the distribution of drugs in normal tissues, which greatly reduces the adverse reactions. To some extent, this advantage makes up for the shortcomings of common chemotherapeutic drugs. Glycyrrhetinic acid has attracted more and more attention because of its effective liver targeting, and it is used as a carrier to play a more and more important role in liver targeting. In this paper, the structure modification of glycyrrhetinic acid and the research status of related nano-preparations in liver targeting research are summarized, which provides a reference for the study of liver-targeted preparation of glycyrrhetinic acid.
【作者單位】： 江西中醫(yī)藥大學藥學院;
【分類號】：R943

【相似文獻】

相關(guān)期刊論文 前10條

1 王蔚;袁直;;肝靶向納米給藥系統(tǒng)的最新研究進展[J];高分子通報;2013年01期

2 郭影坤;隋陽;;藥物在體內(nèi)分布及肝靶向性研究[J];當代化工;2013年03期

3 鄢國平,卓仁禧,徐勉懿,李麗云,唐岳楓;肝靶向性聚天冬酰胺磁共振成像造影劑[J];中國科學(B輯 化學);2001年03期

4 張立堅;蔡春;蔡康榮;徐美奕;蘇敏;楊健;;肝靶向前藥Gal-HSA-RA的制備及特性[J];廣西醫(yī)科大學學報;2007年02期

5 張闖年;王平;賴全勇;張倩;張s，

本文編號：1989130